Sunday, February 1

Healthcare

FDA accepts SpringWorks' application for mirdametinib for NF1-PN

08/29/20241 Min Read

accepts application FDA mirdametinib NF1PN SpringWorks039

Previous ArticlePfizer in collaboration with Quotient Therapeutics for CV, kidney disease therapies

Next Article Krystal Biotech's Jeune reports promising phase 1 data on wrinkles drug